L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma

This study tests L218CAR19, an experimental CAR-T cell therapy, in patients with B-cell lymphoma (a blood cancer) that has returned or stopped responding to at least two prior treatments, including rituximab-based therapy. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed CD19-positive B-cell lymphoma that has relapsed or is refractory after at least two prior lines of treatment - You have measurable disease on imaging - Your overall health is adequate (ECOG 0–2) with adequate organ and blood count function **You may NOT be eligible if...** - You have less than 3 months expected survival - Your blood counts or organ function are below required thresholds - You have active uncontrolled infection - You have had prior CAR-T therapy that your lymphoma no longer responds to (unless CD19 expression is confirmed) Talk to your doctor to see if this trial is right for you.